ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO267

Dialysate Buffer in Hemodialysis: Effect of Practice Patterns on Serum PTH

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis


  • Urena Torres, Pablo A., Aura Paris, Paris, France
  • Seris, Pascal, Aura Paris, Paris, France
  • Kolko-Labadens, Anne, Aura Paris, Paris, France
  • Chazot, Charles, Aura Paris, Paris, France

We report the analysis of 3 dialysate (D) acidic buffers on serum PTH in 4 dialysis units in Paris (France) area.


Data from prevalent hemodialysis (HD) patients (pts) treated in 4 units were collected in the 4th quarter 2022 and analyzed with Kruskal-Wallis and stepwise logistic regression tests. The biology lab is common to the 4 units. PTH was assessed using the Architect Intact PTH assay®.


The 529 pts were 64 y.o. with 35% females, dialysis vintage: 47 months, Charlson index: 10. The acidic buffers were acetate (30.7%), hydrochloric acid (HCl) (35.7%) and citric acid (citrate) (33.6%). Pts on acetate were significantly younger (59 years) versus 67.5 and 66 years on HCl and citrate (p=0.001), with a lower Charlson index (9 versus 10 (0.001). Pts on HCl had significantly lower serum PTH levels; serum magnesium was significantly lower in citrate group; calcium, phosphate, native vitamin D were not different (Table 1). Muscle cramps during the dialysis were found in 10.2% (citrate), 8.5% (HCl) and 6.2% (acetate, p=0.027). The D calcium is reported in Table 1. The proportion of pts on calcimimetics and active vitamin D did not differ between groups. Factors associated with a PTH >612 pg/ml were age (-0.012, p<0.04), acetate buffer (0.065, p<0.001) and calcimimetic prescription (0.76; p<0.001). Conversely, only dialysis vintage was associated with a PTH < 130pg/ml (0.07; p=0.0066).


The use of citrate D in this cohort was not associated with a higher PTH compared to pts on acetate or HCl. The large prescription of D calcium at 1,65 mmoles/l in the citrate group may have helped to avoid low ionized calcium. Higher muscle cramps and lower magnesium were findings already reported with the use of citrate D and confirmed in this cohort. Dialysis with citrate or HCl are possible alternatives when avoiding acetate buffer is wanted. Increasing D magnesium to avoid cramps remains to be studied.

Calcium (mmol/l)2,20 (2,13-2,29)2,19 (2.12-2,26)2,10 (2,12-2,27)NS
Phosphate (mmol/l)1,31 (1,06-1,59)1,315 (1,13-1,55)1,30(1,15-1,545)NS
Magnesium (mmol/l)0.90 (0,83-0;97)0.86 (0,77-0;93)0.88 (0,805-0,95)< 0.001
PTH (pg/ml)526 (324-861)421 (226-671)318 (189-582)< 0.001
25OHD (ng/ml)39,5 (29,5-50,28)40,54 (33,37-49,67)39,90 (34,37-42,22)NS
Bone-specific alkaline phosphatase (ng/ml)28.9 (20.3-49.1)23.0 (17.4-35.1)26.6 (18.1-40.7)NS
Calcium dialysate (mmol/l)
0.6 %
75.9 %
0 %
23.5 %
0.6 %
0 %
72.9 %
26.6 %
1.1 %
65.5 %
0 %
33.5 %